---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-003019"
form_type: "8-K"
ticker: "IDXG"
cik: "0001054102"
company_name: "INTERPACE BIOSCIENCES, INC."
filed_at: "2025-01-21T23:59:59+00:00"
generated_at: "2026-05-27T21:51:08.406198+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Interpace restructures debt and cuts workforce after CMS drops PancraGEN coverage

## Summary
- Fourth Amendment: monthly $500k principal payments Feb-Jun 2025, interest-only Jul-Dec, final balance due Dec 31, 2025; 1% restructuring fee paid on Jan 17, 2025.
- Board approved restructuring plan Jan 14, 2025 due to CMS ending PancraGEN coverage (announced Jan 9, 2025).
- Workforce reduction; severance costs estimated $0.8M–$1.0M, primarily recorded in Q1 2025.
- Expected annual cost savings of $12.5M–$14.5M, expected to offset approximately one-third of revenue loss from PancraGEN.

## SEC filing metadata
- accession: 0001493152-25-003019
- form_type: 8-K
- ticker: IDXG
- cik: 0001054102
- company_name: INTERPACE BIOSCIENCES, INC.
- filed_at: 2025-01-21T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.03, 2.05
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1054102/000149315225003019/0001493152-25-003019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1054102/000149315225003019/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-003019
- JSON: https://secwatch.observer/filing/0001493152-25-003019.json
- Plain text: https://secwatch.observer/filing/0001493152-25-003019.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.